Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Plasma Free Fatty Acids and Metabolic Effect in Type 2 Diabetes, an Ancillary Study from a Randomized Clinical Trial.

Tytuł:
Plasma Free Fatty Acids and Metabolic Effect in Type 2 Diabetes, an Ancillary Study from a Randomized Clinical Trial.
Autorzy:
Mitri J; Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA.
Tomah S; Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA.
Furtado J; Department of Nutrition, Harvard T. H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA.
Tasabehji MW; Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA.
Hamdy O; Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA.
Źródło:
Nutrients [Nutrients] 2021 Mar 31; Vol. 13 (4). Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI Publishing
MeSH Terms:
Dairy Products*
Nutrition Assessment*
Fatty Acids, Nonesterified/*blood
Aged ; Biomarkers/blood ; Body Weight ; Cardiovascular Diseases ; Diabetes Mellitus, Type 2 ; Diet ; Female ; Glycated Hemoglobin/metabolism ; Humans ; Male ; Middle Aged ; Risk Factors
References:
Circulation. 2016 Apr 26;133(17):1645-54. (PMID: 27006479)
Am J Epidemiol. 1997 Jun 15;145(12):1114-22. (PMID: 9199541)
Am J Clin Nutr. 2017 Mar;105(3):723-735. (PMID: 28202478)
Metabolism. 2010 Jan;59(1):86-92. (PMID: 19766268)
PLoS One. 2013 Oct 11;8(10):e76480. (PMID: 24146877)
Am J Clin Nutr. 2020 Aug 1;112(2):293-302. (PMID: 32520346)
J Nutr. 2020 Feb 1;150(2):340-349. (PMID: 31618417)
Am J Clin Nutr. 1998 Aug;68(2):291-5. (PMID: 9701185)
Diabetes Care. 2018 Aug;41(8):1732-1739. (PMID: 29844096)
BMC Med. 2014 Nov 25;12:215. (PMID: 25420418)
J Lipid Res. 2017 Nov;58(11):2171-2179. (PMID: 28928169)
Ann Intern Med. 2010 Dec 21;153(12):790-9. (PMID: 21173413)
Metabolism. 2014 May;63(5):618-27. (PMID: 24636056)
Eur J Clin Nutr. 2011 Sep;65(9):1027-31. (PMID: 21559046)
Am J Clin Nutr. 2014 Jun;99(6):1385-96. (PMID: 24740208)
Am J Clin Nutr. 2002 Oct;76(4):750-7. (PMID: 12324287)
Ann Intern Med. 2014 Mar 18;160(6):398-406. (PMID: 24723079)
Curr Opin Lipidol. 1996 Feb;7(1):34-7. (PMID: 8925187)
Am J Clin Nutr. 2015 May;101(5):1065-80. (PMID: 25832335)
Am J Clin Nutr. 2015 May;101(5):1102-3. (PMID: 25934871)
Am J Clin Nutr. 2015 May;101(5):1047-54. (PMID: 25787996)
Diabetes Metab Syndr. 2019 Sep - Oct;13(5):2879-2887. (PMID: 31425952)
Grant Information:
P30 DK036836 United States DK NIDDK NIH HHS; Contract# 25100 National Dairy Council
Contributed Indexing:
Keywords: dairy; diabetes; fatty acids
Substance Nomenclature:
0 (Biomarkers)
0 (Fatty Acids, Nonesterified)
0 (Glycated Hemoglobin A)
0 (hemoglobin A1c protein, human)
Entry Date(s):
Date Created: 20210403 Date Completed: 20210602 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC8065525
DOI:
10.3390/nu13041145
PMID:
33807135
Czasopismo naukowe
Most nutrition studies looking at the association of food with cardiometabolic markers rely on food frequency questionnaires, which are prone to recall bias. Pentadecanoic acid, heptadecanoic acid and trans-palmitoleic acid are fatty acids that are not synthesized endogenously but are obtained from the diet, particularly dairy, making them reasonable biomarkers of dairy consumption. We investigated the association of dairy fatty acid biomarkers with glycated hemoglobin (HbA1c) and cardiovascular risk factors in type 2 diabetes (T2D). In a clinical trial, 111 participants with T2D (age 58.5 ± 8.9 years, HbA1c 8.09 ± 0.96%) were randomized into three groups: a control group that maintained baseline dairy intake, a low-fat (LF) group that incorporated ≥3 servings/day of LF dairy and a high-fat (HF) group that incorporated ≥3 servings/day of HF dairy. We compared the fatty acids (FA) composition between the three groups at 24 weeks. Pentadecanoic acid and trans-palmitoleic acid increased in the HF group by 14.1% ± 5.4% and 17.5% ± 5.1%, respectively, but not in the control and LF groups ( p = 0.0474 and p = 0.0025 for group-by-time interaction, respectively). Those increases were positively associated with changes in total cholesterol, very-low-density lipoprotein cholesterol VLDL-C and triglycerides but were not associated with changes in HbA1c from baseline to 24 weeks. These results suggest that the intervention was successful and that participants were likely compliant, which supports the validity of the main trial.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies